Hubei Goto Biopharm Co.,Ltd. (SHE:300966)
China
· Delayed Price · Currency is CNY 27.40
+2.39 (9.56%)
Apr 30, 2026, 1:55 PM CST
Hubei Goto Biopharm Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2018 |
| Net Income | -81.73 | -27.59 | 23.01 | 40.21 | 78.33 | Upgrade
|
| Depreciation & Amortization | 115.41 | 43.24 | 28.21 | 27.23 | 23.36 | Upgrade
|
| Other Amortization | 3.33 | 3.31 | 2.83 | 0.81 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.44 | -0.11 | -0.17 | 0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 14.35 | 10.46 | 2.23 | 0.96 | 3.47 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.29 | 0.35 | -0.17 | 0.04 | -0 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 4.22 | 4.45 | 4.87 | - | Upgrade
|
| Other Operating Activities | 53.56 | 25.09 | 19.79 | 11.52 | 7.76 | Upgrade
|
| Change in Accounts Receivable | 25.47 | 8.56 | -60.59 | -34.66 | 20.23 | Upgrade
|
| Change in Inventory | -99.52 | -43.31 | -9.76 | -60.43 | -173.33 | Upgrade
|
| Change in Accounts Payable | 34.6 | -29.83 | 62.04 | -6.5 | 103.58 | Upgrade
|
| Change in Other Net Operating Assets | -1.66 | -0.03 | 1.69 | - | - | Upgrade
|
| Operating Cash Flow | 41.04 | -20.59 | 68.13 | -24.04 | 58 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 330.46% | Upgrade
|
| Capital Expenditures | -166.33 | -311.61 | -409.25 | -407.94 | -90.91 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.18 | 0.12 | - | 0.13 | - | Upgrade
|
| Investment in Securities | - | - | 15.02 | -48.5 | -14.5 | Upgrade
|
| Other Investing Activities | - | 17.16 | -8.11 | 0 | - | Upgrade
|
| Investing Cash Flow | -166.14 | -294.34 | -402.35 | -456.3 | -105.41 | Upgrade
|
| Long-Term Debt Issued | 468.38 | 723.59 | 323.2 | 953.57 | 160 | Upgrade
|
| Total Debt Issued | 468.38 | 723.59 | 323.2 | 953.57 | 160 | Upgrade
|
| Long-Term Debt Repaid | -326.06 | -434.2 | -319.88 | -250.44 | -156.77 | Upgrade
|
| Total Debt Repaid | -326.06 | -434.2 | -319.88 | -250.44 | -156.77 | Upgrade
|
| Net Debt Issued (Repaid) | 142.32 | 289.39 | 3.32 | 703.12 | 3.23 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 208.16 | Upgrade
|
| Common Dividends Paid | -29.83 | -25.69 | -6.09 | -26.91 | -7.58 | Upgrade
|
| Other Financing Activities | -22.3 | 55.7 | 18.37 | 37.08 | 3.18 | Upgrade
|
| Financing Cash Flow | 90.19 | 319.4 | 15.59 | 713.3 | 207 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.06 | -0.56 | -0.32 | 0.28 | -0.44 | Upgrade
|
| Net Cash Flow | -34.98 | 3.92 | -318.94 | 233.23 | 159.16 | Upgrade
|
| Free Cash Flow | -125.29 | -332.2 | -341.12 | -431.98 | -32.91 | Upgrade
|
| Free Cash Flow Margin | -20.67% | -61.91% | -60.23% | -71.45% | -5.57% | Upgrade
|
| Free Cash Flow Per Share | -1.09 | -2.89 | -2.97 | -3.76 | -0.31 | Upgrade
|
| Cash Interest Paid | - | 0.3 | - | - | - | Upgrade
|
| Cash Income Tax Paid | -33.08 | -47.25 | -39.05 | -13.81 | 17.33 | Upgrade
|
| Levered Free Cash Flow | -115.99 | -294.86 | 10.86 | -403.28 | -57.11 | Upgrade
|
| Unlevered Free Cash Flow | -115.99 | -280.17 | 19.1 | -394.73 | -53.87 | Upgrade
|
| Change in Working Capital | -65.63 | -79.56 | -12.04 | -109.68 | -54.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.